当前位置：
X-MOL 学术
›
J Neurooncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Correction to: White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
Journal of Neuro-Oncology ( IF 3.2 ) Pub Date : 2019-12-01 , DOI: 10.1007/s11060-019-03346-1 Fayez Estephan 1 , Xiaobu Ye 1, 2 , Omar Dzaye 1, 3, 4 , Nina Wagner-Johnston 1 , Lode Swinnen 1 , Douglas E Gladstone 1 , Rich Ambinder 1 , David Olayinka Kamson 1 , Sebastian Lambrecht 3 , Stuart A Grossman 1 , Doris D M Lin 3, 5 , Matthias Holdhoff 1, 6
Journal of Neuro-Oncology ( IF 3.2 ) Pub Date : 2019-12-01 , DOI: 10.1007/s11060-019-03346-1 Fayez Estephan 1 , Xiaobu Ye 1, 2 , Omar Dzaye 1, 3, 4 , Nina Wagner-Johnston 1 , Lode Swinnen 1 , Douglas E Gladstone 1 , Rich Ambinder 1 , David Olayinka Kamson 1 , Sebastian Lambrecht 3 , Stuart A Grossman 1 , Doris D M Lin 3, 5 , Matthias Holdhoff 1, 6
Affiliation
The following discrepancies and errors were found in the original publication.
中文翻译：
校正至：接受或不接受利妥昔单抗的大剂量甲氨蝶呤治疗的原发中枢神经系统淋巴瘤患者的白质变化。
在原始出版物中发现以下差异和错误。
更新日期：2019-11-22
中文翻译：
校正至：接受或不接受利妥昔单抗的大剂量甲氨蝶呤治疗的原发中枢神经系统淋巴瘤患者的白质变化。
在原始出版物中发现以下差异和错误。
京公网安备 11010802027423号